Trial details
INVESTIGATING THE POTENTIAL OF SHORT-TERM PATIENT DERIVED XENOGRAFTS FOR PERSONALIZED MEDICINE FOR PATIENTS WITH METASTATIC SOLID TUMORS: A Non-interventional Clinical Trial.
To find out more about this trial and your cancer treatment options, please speak with your doctor.
Trial short name: PDXovo
Official title: INVESTIGATING THE POTENTIAL OF SHORT-TERM PATIENT DERIVED XENOGRAFTS FOR PERSONALIZED MEDICINE FOR PATIENTS WITH METASTATIC SOLID TUMORS: A Non-interventional Clinical Trial.
Principal Investigator: Dr. Hon Leong
Cancer type: Genitourinary
Cancer location: Genitourinary
Disease stage: Early Cancer
Trial phase:
Intervention: Pre-clinical Observational
Registration #:
NCT04602702 
Contact e-mail: cancerclinicaltrials@sunnybrook.ca
Trial description:
The Investigators will use novel PDX (patient-derived xenograft) technology to form xenografts using material from metastatic solid tumor patients. Xenografts will be treated with a panel of drugs to determine which agent(s) yield the greatest anti-tumor effect on the xenograft.
Patient eligibility: Localized solid tumor inclusion criteria: i) Age 18+ ii) localized solid tumor irrespective of subtype undergoing curative surgery iii) Consent to provide tumor tissue for this research Metastatic cancer inclusion criteria: i) Age 18+ ii) metastatic cancer irrespective of subtype undergoing a needle biopsy or resection of lung, liver or brain as part of their routine clinical care. iii) metastatic cancer irrespective of disease site undergoing a thoracentesis or paracentesis as part of their routine clinical care. iv) measurable disease as per RECIST 1.1 criteria v) Consent to provide tumor tissue for this research
